Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1206 vs Xgeva PK/PD in Healthy Adults
NCT03651947Phase 1Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Aug 2018
- Primary completion
- Nov 2018
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of QL1206 in bone metastases and Giant Cell Tumor of Bone (GCTB) (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Area under the plasma concentration-time curve from time zero to the last measurable concentration at 134 days. Started Aug 2018; status: completed.
02
Drugs
QL1206
03
Conditions
bone metastasesGiant Cell Tumor of Bone (GCTB)
Beyond the preview
Go deeper on NCT03651947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03651947.